GlassScriptPhysician profile
Mackenzie Mae Smith
NPI 1306515804
$2,514.99
in general payments reported to CMS, 2019-2025
21 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $536 · 2024: $837 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,514.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $335.06 | 2023-2025 | Intellis Adaptivestim, Synchromedii, Vanta Adaptivestim |
| Collegium Pharmaceutical, INC. | $331.07 | 2023-2025 | Belbuca, Nucynta |
| Abbott Laboratories | $274.87 | 2025 | Proclaim, Eterna |
| Spinal Simplicity, LLC | $269.89 | 2024-2025 | Ha Minuteman G3-R |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.14 | 2024-2025 | Relistor |
| Pfizer INC. | $158.53 | 2024-2025 | |
| Abbvie INC. | $150.13 | 2025 | |
| Boston Scientific Corporation | $146.38 | 2024 | Wavewriter Alpha Prime 16, Infinion 16 |
| Axsome Therapeutics, INC. | $121.36 | 2025 | Symbravo |
| Saluda Medical Americas, INC. | $110.52 | 2024-2025 | Evoke |
| Vertex Pharmaceuticals Incorporated | $100.90 | 2024-2025 | |
| Almatica Pharma LLC | $77.72 | 2023 | Gralise, Loreev Xr |
| Si-Bone, INC. | $75.38 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $36.48 | 2024-2025 | Ajovy |
| Ibsa Pharma INC. | $31.05 | 2023-2025 | Tirosint, Flector, Licart |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spr Therapeutics, INC | $28.79 | 2023-2025 | Sprint Pns System |
| Tonix Medicines, INC. | $25.42 | 2025 | Tonmya |
| Globus Medical, INC. | $25.20 | 2025 | Senza |
| Pacira Pharmaceuticals Incorporated | $18.79 | 2025 | Exparel, Zilretta, Iovera |
| Heron Therapeutics, INC. | $18.60 | 2025 | Zynrelef |
| Lilly USA, LLC | $12.71 | 2023 | Emgality, Reyvow |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.